What do systematic reviews say?

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant targeted treatment (BRAF/MEK inhibition) changes overall survival (OS), measured by number of deaths over time,Median compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.28 [0.03, 2.25]
  1 study · 21 participants
  Very low

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 14 participants
  Low

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 13 participants
  Low

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant targeted treatment (BRAF/MEK inhibition) changes time to recurrence (TTR), measured by the number of disease… compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.02 [0, 0.22]
  1 study · 21 participants
  Very low